Alnylam Pharmaceuticals (NASDAQ:ALNY) on Saturday released additional data from its Phase 3 HELIOS-B trial, which evaluated its recently approved RNAi therapy Amvuttra (vutrisiran) in patients with ATTR amyloidosis with cardiomyopathy, a heart disorder.

Based on a follow-up analysis through up